Evidence map›Paper›PMID 31683543›Full record

ReviewInternational journal of molecular sciences2019

Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis.

Masutaka Furue, Akiko Hashimoto-Hachiya, Gaku Tsuji

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05186805 (Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis), which is not on this map. Cited by 126 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 1 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05186805 phase2completednot on this mapstarted 2021, after this paper: background citation

Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

TypeinterventionalSponsorOrganon and CoRan2021 to 2022Enrolled36ConditionsAtopic DermatitisArmsTapinarof cream, 1%
3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 1 synthesis or guideline pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Masutaka FurueDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan. furue@dermatol.med.kyushu-u.ac.jp.ORCID 0000-0002-2967-1073
Akiko Hashimoto-HachiyaDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan. ahachi@dermatol.med.kyushu-u.ac.jp.
Gaku TsujiDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan. gakku@dermatol.med.kyushu-u.ac.jp.
Kyushu University · JP

Funding

The Leading Advanced Projects for Medical Innovation in Japan The Leading Advanced Projects for Medical Innovation in JapanThe Ministry of Health, Labour, and Welfare in Japan H30-Shokuhin-Shitei-005
6 · The paper itself

Abstract

The aryl hydrocarbon receptor (AHR)/AHR-nuclear translocator (ARNT) system is a sensitive sensor for small molecular, xenobiotic chemicals of exogenous and endogenous origin, including dioxins, phytochemicals, microbial bioproducts, and tryptophan photoproducts. AHR/ARNT are abundantly expressed in the skin. Once activated, the AHR/ARNT axis strengthens skin barrier functions and accelerates epidermal terminal differentiation by upregulating filaggrin expression. In addition, AHR activation induces oxidative stress. However, some AHR ligands simultaneously activate the nuclear factor-erythroid 2-related factor-2 (NRF2) transcription factor, which is a master switch of antioxidative enzymes that neutralizes oxidative stress. The immunoregulatory system governing T-helper 17/22 (Th17/22) and T regulatory cells (Treg) is also regulated by the AHR system. Notably, AHR agonists, such as tapinarof, are currently used as therapeutic agents in psoriasis and atopic dermatitis. In this review, we summarize recent topics on AHR related to atopic dermatitis and psoriasis.

Indexed as

Polymorphism, Single NucleotideAnimalsDermatitis, AtopicFilaggrin ProteinsHumansOxidative StressPsoriasisReceptors, Aryl HydrocarbonSkinT-Lymphocytes, Helper-InducerT-Lymphocytes, RegulatoryFilaggrin ProteinsFLG protein, humanReceptors, Aryl Hydrocarbonantioxidantsaryl hydrocarbon receptor (AHR)aryl hydrocarbon receptor-nuclear translocator (ARNT)atopic dermatitisfilaggrinnuclear factor-erythroid 2-related factor-2 (NRF2)psoriasisreactive oxygen speciesskin barriertapinarofTh17Th22Treg

Identifiers

PMID31683543
PMCPMC6862295
OpenAlexW2982429666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.